Furthermore, their ability to lower systolic blood pressure without causing hypotension is a major advantage
Consumers may think theyre getting a blockbuster GLP-1 drug like semaglutide the active ingredient in Ozempic and Wegovy or tirzepatide the active ingredient in Mounjaro and Zepbound in a format thats applied to the skin
Clinical trials show that patients average 2 to 5 pounds in the first 4 weeks of semaglutide therapy, depending on starting dose, adherence, and individual metabolism
Altogether, muscle loss during GLP1RAs therapy is multifactorial, involving reduced protein intake and negative energy balance, hormonal adaptations, impaired mTOR signaling and protein synthesis, increased proteolysis and potential mitochondrial adaptations, and age, frailty, and physical inactivity as modifiers (Fig
The benefits of Wegovy treatments extend beyond weight loss